Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCELLULAR AND MOLECULAR

Inhibition of Histone Deacetylases by Chlamydocin Induces Apoptosis and Proteasome-Mediated Degradation of Survivin

Stefanie De Schepper, Hélène Bruwiere, Tinne Verhulst, Ulf Steller, Luc Andries, Walter Wouters, Michel Janicot, Janine Arts and Jim Van heusden
Journal of Pharmacology and Experimental Therapeutics February 2003, 304 (2) 881-888; DOI: https://doi.org/10.1124/jpet.102.042903
Stefanie De Schepper
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hélène Bruwiere
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tinne Verhulst
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulf Steller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luc Andries
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Walter Wouters
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel Janicot
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janine Arts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jim Van heusden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The naturally occurring cyclic tetrapeptide chlamydocin is a very potent inhibitor of cell proliferation. Here we show that chlamydocin is a highly potent histone deacetylase (HDAC) inhibitor, inhibiting HDAC activity in vitro with an IC50 of 1.3 nM. Like other HDAC inhibitors, chlamydocin induces the accumulation of hyperacetylated histones H3 and H4 in A2780 ovarian cancer cells, increases the expression of p21cip1/waf1, and causes an accumulation of cells in G2/M phase of the cell cycle. In addition, chlamydocin induces apoptosis by activating caspase-3, which in turn leads to the cleavage of p21cip1/waf1 into a 15-kDa breakdown product and drives cells from growth arrest into apoptosis. Concomitant with the activation of caspase-3 and cleavage of p21cip1/waf1, chlamydocin decreases the protein level of survivin, a member of the inhibitor of apoptosis protein family that is selectively expressed in tumors. Although our data indicate a potential link between degradation of survivin and activation of the apoptotic pathway induced by HDAC inhibitors, stable overexpression of survivin does not suppress the activation of caspase-3 or cleavage of p21cip1/waf1 induced by chlamydocin treatment. The decrease of survivin protein level is mediated by degradation via proteasomes since it can be inhibited by specific proteasome inhibitors. Taken together, our results show that induction of apoptosis by chlamydocin involves caspase-dependent cleavage of p21cip1/waf1, which is strikingly associated with proteasome-mediated degradation of survivin.

Footnotes

  • ↵1 Current address: GIMV, Venture Capital–Life Sciences. E-mail: jimvh{at}gimv.be

  • DOI: 10.1124/jpet.102.042903

  • Abbreviations:
    HAT
    histone acetyltransferase
    HDAC
    histone deacetylase
    Z-VAD-fmk
    benzyloxycarbonyl-Val-Ala-Asp(O-Me)-fluoromethyl ketone
    Z-DEVD-fmk
    benzyloxycarbonyl-Asp-Glu(OMe)-Val-Asp(O-Me)-fluoromethyl ketone
    MG132
    Z-Leu-Leu-Leu-aldehyde
    MTT
    3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide
    EGFP
    enhanced green fluorescent protein
    tTA
    tetracycline controlled transcriptional activator
    • Received August 6, 2002.
    • Accepted October 4, 2002.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 304 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 304, Issue 2
1 Feb 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibition of Histone Deacetylases by Chlamydocin Induces Apoptosis and Proteasome-Mediated Degradation of Survivin
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCELLULAR AND MOLECULAR

Inhibition of Histone Deacetylases by Chlamydocin Induces Apoptosis and Proteasome-Mediated Degradation of Survivin

Stefanie De Schepper, Hélène Bruwiere, Tinne Verhulst, Ulf Steller, Luc Andries, Walter Wouters, Michel Janicot, Janine Arts and Jim Van heusden
Journal of Pharmacology and Experimental Therapeutics February 1, 2003, 304 (2) 881-888; DOI: https://doi.org/10.1124/jpet.102.042903

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCELLULAR AND MOLECULAR

Inhibition of Histone Deacetylases by Chlamydocin Induces Apoptosis and Proteasome-Mediated Degradation of Survivin

Stefanie De Schepper, Hélène Bruwiere, Tinne Verhulst, Ulf Steller, Luc Andries, Walter Wouters, Michel Janicot, Janine Arts and Jim Van heusden
Journal of Pharmacology and Experimental Therapeutics February 1, 2003, 304 (2) 881-888; DOI: https://doi.org/10.1124/jpet.102.042903
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Role of ERK1/2 Signaling in Stc2-Mediated Protection
  • Topical arsenicals and transcriptional changes in the kidney
  • Effect of CBG and EAA on UVA-irradiated keratinocytes
Show more Cellular and Molecular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics